ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed breast cancer that is metastatic (Stage IV) or locally advanced recurrent breast cancer that is unresectable and for which standard curative or palliative measures do not exist or are no longer effective. * Measurable disease by RECIST criteria * All immunohistochemical subtypes of breast cancer are eligible. HER2 positive breast cancer must have progressed on prior standard HER2 therapy or have a contraindication to anti-HER2 therapy. * Must have at least 1 prior chemotherapy regimen for metastatic disease, with no limit on total number of prior therapies. * 18 years of age or older * Life expectancy of at least 12 weeks * ECOG Performance Status of 0, 1, or 2 * Normal organ and marrow function as outlined in the protocol * Archived tissue block or 25 unstained slides (from primary and/or metastatic tumor) if available for correlative exploratory studies. Absence of available tissue will not exclude the subjects from participating. * CNS metastases are allowed if they are clinically stable without current evidence of symptomatic progression and do not require steroids, whole brain radiation therapy, or stereotactic radiosurgery. This may include brain metastases not previously treated if they are clinically stable as described above. * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * Women of child-bearing poten…